1. Home
  2. IBRX vs DY Comparison

IBRX vs DY Comparison

Compare IBRX & DY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

N/A

Current Price

$8.24

Market Cap

8.2B

Sector

Health Care

ML Signal

N/A

Logo Dycom Industries Inc.

DY

Dycom Industries Inc.

N/A

Current Price

$233.29

Market Cap

9.3B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
IBRX
DY
Founded
2014
1969
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Water Sewer Pipeline Comm & Power Line Construction
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
9.3B
IPO Year
2015
1995

Fundamental Metrics

Financial Performance
Metric
IBRX
DY
Price
$8.24
$233.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
12
Target Price
$14.25
★ $513.18
AVG Volume (30 Days)
★ 13.5M
580.6K
Earning Date
11-10-2026
11-18-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 38.71
20.71
EPS
N/A
★ 6.81
Revenue
★ $113,288,000.00
N/A
Revenue This Year
$99.98
$36.81
Revenue Next Year
$108.29
$12.96
P/E Ratio
★ N/A
$35.30
Revenue Growth
★ 668.31
N/A
52 Week Low
$1.95
$215.28
52 Week High
$12.43
$566.47

Technical Indicators

Market Signals
Indicator
IBRX
DY
Relative Strength Index (RSI) 43.83 32.46
Support Level $7.71 $215.28
Resistance Level $8.51 $294.45
Average True Range (ATR) 0.71 10.61
MACD -0.13 0.51
Stochastic Oscillator 18.18 30.83

Price Performance

Historical Comparison
IBRX
DY

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

About DY Dycom Industries Inc.

Dycom Industries Inc is a provider of specialty contracting services to the telecommunications infrastructure and utility industries throughout the United States. The company has two reporting segments: Communications and Building Systems. The Communications segment provides specialty contracting services, including program management, planning; engineering and design; aerial, underground, and wireless construction; maintenance; and fulfillment services for telecommunications and digital infrastructure providers. The Building Systems segment specializes in providing comprehensive building infrastructure solutions, including electrical, energy management, security, and fire safety systems for data centers and other critical facilities. The firm generates key revenue from Communications.

Share on Social Networks: